The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Understanding The Role Of Three-dimensional Genome Organisation In B Cell Lineage Commitment And Leukaemia.
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Every one of your nuclei contain 2 metres of DNA. This DNA is 300,000 times longer than the nucleus itself. In order to fit into this space, while maintaining access to crucial genes, the DNA forms a fantastically ordered three-dimensional structure. This intricate organisation is crucial to health, with even minute changes driving diseases, such as cancer and heart disease. We propose using new technology to understand how this organisation changes during immune cell development and leukaemia.
Structure And Composition Of The Pre-T Cell Receptor-CD3 Complex
Funder
National Health and Medical Research Council
Funding Amount
$307,946.00
Summary
In order to recognize a wide variety of pathogens, humans produce many different T cell receptors (TCRs) by the process of gene-rearrangement. However, gene-rearrangement may not always lead to a functioning TCR. We are studying the pre-TCR protein that is responsible for monitoring the success of gene-rearrangement and is thus essential for the formation of a robust immune system. Understanding pre-TCR function will lead to new treatments for immune related diseases.
Identification And Characterisation Of Novel Genetic Alterations In High Risk Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$315,336.00
Summary
Acute lymphoblastic leukaemia (ALL) remains the leading cause of cancer-related death in children and young adults. The goal of this research is to identify genetic abnormalities that contribute to treatment failure in high-risk ALL. In addition to providing insights into the biologic basis of ALL, this work has the potential to result in new diagnostic tests, predict response to chemotherapy, and identify new strategies to improve the treatment outcome for ALL patients.
Discovery Of New Targets For Therapy That Kills Non-dividing Cancer Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$375,828.00
Summary
I am a clinical haematologist that specialises in treating patients with a terrible form of blood cancer, acute myeloid leukaemia. Survival rates for this disease have not changed for 30 years and we now realise this is because we are not targetting the queen bee of the cancer - the cancer stem cell. In this project I am looking for cell markers that are only present in rare, truly latent non-dividing cancer stem cells effectively change a remission into a cure.
Combinatorial Therapeutics In High-risk Infant Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$340,891.00
Summary
Modern therapies for children with leukaemia are curative in more than 90%. In contrast, survival for infants less than one year of age at the time of diagnosis is less than 50%. Better therapies are desperately needed. From laboratory testing we have discovered effective novel cancer drugs, which are not currently used for treatment of babies with leukaemia. We will evaluate novel drug combinations and test them in model systems, such that they can be fast-tracked to the clinic.
Investigating The Gene And Gene Expression Differences In The Cells That Drive Leukemia Development And Relapse In Children With AML
Funder
National Health and Medical Research Council
Funding Amount
$388,612.00
Summary
Current treatments for AML are initially effective at killing the majority of leukemic cells, but the disease often comes back (relapses) due to rare cells that escape treatment and can regenerate the cancer (called leukemic stem cells or LSC for short). This project aims to determine if an individual patient has one, or many kinds of LSC and which kind of LSC is most likely to cause relapse. We believe that this knowledge will lead to new treatments that can target the cells that cause relapse.
The Role Survivin And XIAP (X-linked Inhibitor Of Apoptosis Protein) As Biomarkers And Therapeutic Targets In Paediatric Acute Myeloid Leukaemia.
Funder
National Health and Medical Research Council
Funding Amount
$294,218.00
Summary
I am a Paediatric Haematologist/Oncologist focussing on new treatments for childhood acute myeloid leukaemia. This study is examining the effects of conventional and novel therapies on two proteins that prevent cell death in acute myeloid leukaemia. The study will also develop clinical trials of new drugs targeting these proteins.
Improving Early Recognition And Response To Symptoms In Acute Cardiovascular Events.
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
An important challenge facing cardiovascular public health is to improve access to treatment for acute events, like heart attacks and stroke, by improving public recognition and the initial response to symptoms. This research aims to extend the current understanding and to evaluate existing and test new interventions in this area. Outcomes from this research will inform the development of future campaigns and interventions aiming to improve symptom recognition and reduce delays in presenting to ....An important challenge facing cardiovascular public health is to improve access to treatment for acute events, like heart attacks and stroke, by improving public recognition and the initial response to symptoms. This research aims to extend the current understanding and to evaluate existing and test new interventions in this area. Outcomes from this research will inform the development of future campaigns and interventions aiming to improve symptom recognition and reduce delays in presenting to hospital for acute cardiovascular events.Read moreRead less
Optimising Outcomes In Chronic Myeloid Leukaemia Through Rational Drug Selection Using Predictive Assay Results And Maximising Treatment Free Remissions
Funder
National Health and Medical Research Council
Funding Amount
$193,596.00
Summary
Although outcomes in chronic myeloid leukaemia are generally excellent, a number of important questions remain. In this grant, we propose to i) personalise the selection of frontline treatment for newly diagnosed patients, using biomarkers which can predict treatment response; ii) improve the probability of cure in patients aiming to stop their treatment, and iii) use ultra-sensitive molecular tests for disease detection to predict risk of disease relapse.